135P - Significance of thyroid transcription factor 1 expression in patients with nonsquamous NSCLC treated with pemetrexed based chemotherapy

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Xabier Mielgo
Citation Annals of Oncology (2015) 26 (suppl_1): 29-44. 10.1093/annonc/mdv050
Authors X. Mielgo1, A. Velastegui Ordoñez1, R. Martínez Cabañes1, A.C. Rosero1, L. Ruiz-Giménez1, J.C. Cámara1, S. Hernando1, A. Hurtado1, C. Olier2, C. Jara2
  • 1Medical Oncology, HUFA Hospital Universitario Fundacion Alcorcon, 28922 - Alcorcon/ES
  • 2Medical Oncology, HUFA Hospital Universitario Fundacion Alcorcon, Alcorcon/ES



There are no demonstrated predictive molecular markers for pemetrexed. The aim of this study is to explore and evaluate whether thyroid transcription factor 1 (TTF1) protein expression can be a predictive biomarker of clinical activity for pemetrexed-based chemotherapy in patients with nonsquamous non-small cell lung cancer (NSCLC).


118 patients with advanced nonsquamous NSCLC treated with pemetrexed-based chemotherapy as first-line, maintenance, second or later-line therapy were retrospectively analyzed for clinicopathological features, immunohistochemical expression of TTF1 and clinical outcomes. Analysis of TTF1 expression was done according to the routine clinical practice of our center.


Immunohistochemical analysis of TTF1 expression was only performed in 46 of the 118 patients reviewed. Of these 46 patients, 33 were men and 13 women, 13% had never smoked and 87% were former or current smokers. Median age was 67 (range 46-79). Performance status (PS) distribution: 0 (23,9%), 1 (65,2%), 2 (8,6%), 3 (2,1%). Predominant histology type was adenocarcinoma (76%), followed by large cell carcinoma (15,2%) and not otherwhise specified-NOS (8,6%). 32 patientes had TTF1-positive tumors (69,5%), and 14 had TTF1-negative ones (30,5%). Tumors with TTF1-positivity were more frequent in patients who were younger, had adenocarcinoma, or had EGFR mutations. TTF1 positivity shown a nonsignificant trend of association with higher disease control rates for pemetrexed-based chemotherapy (80% versus 57,8%, p = 0,111). Median progression free survival (PFS) and overall survival (OS) in the whole group was 5,05 and 24,27 months respectively. TTF1-positive tumors had nonsignificant longer PFS and OS to pemetrexed-based chemotherapy than patients with TTF1-negative tumors (PFS: 6,73 vs 3,64 months, p = 0,1295; OS: 24,27 vs 13,66 months, p = 0,412).


High TTF1 protein expression shown a nonsignificant trend of association with better clinical outcomes in nonsquamous NSCLC patients who were treated with pemetrexed-based chemotherapy. The predictive role of TTF1 expression should be further studied.


All authors have declared no conflicts of interest.